World Journal of Urology

, Volume 30, Issue 6, pp 795–799 | Cite as

Downstaging to non-invasive urothelial carcinoma is associated with improved outcome following radical cystectomy for patients with cT2 disease

  • Matthew K. Tollefson
  • Stephen A. Boorjian
  • Sara A. Farmer
  • Igor Frank
Original Article



Pathologic stage is a critically important prognostic factor after radical cystectomy (RC) that is used to guide the use of secondary therapies. However, the risk of disease recurrence, for patients clinically diagnosed with muscle-invasive tumors who are found not to have muscle-invasive disease at RC are poorly defined. Therefore, we reviewed the long-term outcomes in patients who were downstaged to non-invasive urothelial carcinoma at time of RC.


We identified 1,177 consecutive patients with muscle-invasive urothelial carcinoma of the bladder who underwent radical cystectomy at our institution between 1980 and 1999 without neoadjuvant therapy. Postoperative disease recurrence and survival were estimated using the Kaplan–Meier method and compared using the log rank test. Cox proportional hazard regression models were used to analyze the impact of pathologic stage on survival.


Pathologic downstaging to non-muscle invasive disease was identified in 538 (45.7 %) patients. The 10-year cancer-specific survival was 84.1, 77.4, 71.1 and 58.5 % for those with pT0, pTis, pT1 and pT2 tumors, respectively. On multivariate analysis, the risk of cancer-specific mortality was significantly decreased for patients with non-muscle invasive disease than those with organ-confined muscle invasion (RR−0.39; p = 0.002). There was no difference in disease-specific mortality among patients who had non-invasive (pT0, pTa, or pTis) disease (p = 0.19).


Downstaging from clinical muscle-invasive bladder cancer to non-muscle invasive disease at RC is associated with a significant reduction in cancer-specific mortality. However, even patients with residual non-muscle invasive disease may suffer disease recurrence and require continued surveillance after surgery.


Urothelial carcinoma Pathologic staging Clinical staging Risk stratification 


Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277PubMedCrossRefGoogle Scholar
  2. 2.
    Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666PubMedGoogle Scholar
  3. 3.
    Hollenbeck BK, Miller DC, Dunn RL et al (2005) The effects of stage divergence on survival after radical cystectomy for urothelial cancer. Urol Oncol 23:77PubMedCrossRefGoogle Scholar
  4. 4.
    Shariat SF, Palapattu GS, Karakiewicz PI et al (2007) Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 51:137PubMedCrossRefGoogle Scholar
  5. 5.
    McLaughlin S, Shephard J, Wallen E et al (2007) Comparison of the clinical and pathologic staging in patients undergoing radical cystectomy for bladder cancer. Int Braz J Urol 33:25PubMedCrossRefGoogle Scholar
  6. 6.
    Mehrsai A, Mansoori D, Taheri Mahmoudi M et al (2004) A comparison between clinical and pathologic staging in patients with bladder cancer. Urol J 1:85Google Scholar
  7. 7.
    Ficarra V, Dalpiaz O, Alrabi N et al (2005) Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int 95:786PubMedCrossRefGoogle Scholar
  8. 8.
    Guzzo TJ, Magheli A, Bivalacqua TJ et al (2009) Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer. Urology 74:1276PubMedCrossRefGoogle Scholar
  9. 9.
    deVere White RW, Katz MH, Steinberg GD (2009) The case for neoadjuvant chemotherapy and cystectomy for muscle invasive bladder cancer. J Urol 181:1994–1997PubMedCrossRefGoogle Scholar
  10. 10.
    Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859PubMedCrossRefGoogle Scholar
  11. 11.
    Madersbacher S, Hochreiter W, Burkhard F et al (2003) Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. J Clin Oncol 21:690PubMedCrossRefGoogle Scholar
  12. 12.
    Hotston M, Patel S, Sohail M et al (2006) What is the significance of pT0 at cystectomy? Surg Oncol 15:65PubMedCrossRefGoogle Scholar
  13. 13.
    Isbarn H, Karakiewicz PI, Shariat SF et al (2009) Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. J Urol 182:459PubMedCrossRefGoogle Scholar
  14. 14.
    Svatek RS, Shariat SF, Lasky RE et al (2010) The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 16:4461PubMedCrossRefGoogle Scholar
  15. 15.
    Dimopoulos MA, Moulopoulos LA (1998) Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder. J Clin Oncol 16:1601PubMedGoogle Scholar
  16. 16.
    Volkmer BG, Kuefer R, Bartsch G Jr et al (2005) Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survival. Cancer 104:2384PubMedCrossRefGoogle Scholar
  17. 17.
    Thrasher JB, Frazier HA, Robertson JE et al (1994) Does of stage pT0 cystectomy specimen confer a survival advantage in patients with minimally invasive bladder cancer? J Urol 152:393PubMedGoogle Scholar
  18. 18.
    Herr HW (2001) Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 19:89PubMedGoogle Scholar
  19. 19.
    Solsona E, Iborra I, Collado A et al (2010) Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol 184:475PubMedCrossRefGoogle Scholar
  20. 20.
    Palapattu GS, Shariat SF, Karakiewicz PI et al (2006) Cancer specific outcomes in patients with pT0 disease following radical cystectomy. J Urol 175:1645PubMedCrossRefGoogle Scholar
  21. 21.
    Yiou R, Patard JJ, Benhard H et al (2002) Outcome of radical cystectomy for bladder cancer according to the disease type at presentation. BJU Int 89:374PubMedCrossRefGoogle Scholar
  22. 22.
    Kassouf W, Spiess PE, Brown GA et al (2007) P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol 52:769PubMedCrossRefGoogle Scholar
  23. 23.
    Smith DC, Mackler NJ, Dunn RL et al (2008) Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol 180:2384PubMedCrossRefGoogle Scholar
  24. 24.
    Sagaster P, Flamm J, Flamm M et al (1996) Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer. Eur J Cancer 32A:1320PubMedCrossRefGoogle Scholar
  25. 25.
    Duggan B, Williamson K (2004) Molecular markers for predicting recurrence, progression and outcomes of bladder cancer (do the poster boys need new posters?). Curr Opin Urol 14:277PubMedCrossRefGoogle Scholar
  26. 26.
    Cho KS, Seo HK, Joung JY et al (2009) Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol 182:2625PubMedCrossRefGoogle Scholar
  27. 27.
    Kunju LP, You L, Zhang Y et al (2008) Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. J Urol 180:1928PubMedCrossRefGoogle Scholar
  28. 28.
    Quek ML, Quinn DI, Daneshmand S et al (2003) Molecular prognostication in bladder cancer–a current perspective. Eur J Cancer 39:1501PubMedCrossRefGoogle Scholar
  29. 29.
    Tokunaga H, Shariat SF, Green AE et al (2001) Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. Int J Radiat Oncol Biol Phys 51:16PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Matthew K. Tollefson
    • 1
  • Stephen A. Boorjian
    • 1
  • Sara A. Farmer
    • 2
  • Igor Frank
    • 1
  1. 1.Department of UrologyMayo Medical School and Mayo ClinicRochesterUSA
  2. 2.Department of Health Sciences ResearchMayo Medical School and Mayo ClinicRochesterUSA

Personalised recommendations